Table 3.
Pneumococcal vaccine serotype-specific effectiveness estimates in the first year after vaccination for healthy and, immunocompetent with comorbidities, and immunocompromised adult populations
| Manifestation, age at vaccination (years) | Vaccine effectiveness estimates | ||
|---|---|---|---|
| Healthy (%)a | Immunocompetent with comorbidities (%)a | Immunocompromised (%)b | |
| Invasive pneumococcal disease (IPD) | |||
| PPSV23 | |||
| 50 | 82.7 | 70.3 | 18.0 |
| 65 | 73.8 | 62.7 | 16.1 |
| PCV13 | |||
| 50 | 80.0 | 67.5 | 53.0 |
| 65 | 72.5 | 61.2 | 48.0 |
| Non-bacteremic pneumococcal pneumonia (NBPP) | |||
| PPSV23 | |||
| 50 | 49.5 | 36.5 | 0 |
| 65 | 36.5c | 26.9 | 0 |
| PCV13 | |||
| 50 | 68.0 | 56.0 | 7.0 |
| 65 | 60.5 | 49.8 | 6.2 |
ACIP, Advisory Committee on Immunization Practices; PCV13, 13-valent pneumococcal conjugate vaccine; PPSV23, 23-valent pneumococcal polysaccharide vaccine; UBC, United BioSource Corporation
aSource for effectiveness assumptions for healthy and immunocompetent with comorbidities based on internal report from UBC Delphi panel report (October 29, 2011)
bSource for immunocompromised effectiveness assumptions: June 2012 ACIP presentation [14]. UBC Delphi panel did not collect estimates for immunocompromised population, so data from 2012 ACIP analysis was used
cConsensus of the Delphi panel was not reached for this estimate. The a priori protocol defined consensus as 70% of panelist estimates falling within one standard deviation of the mean. For this estimate 60% of estimates were within one standard deviation of the mean